Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 3:40 PM GMT / 10:40 AM EST on Tuesday, November 16, 2021.

The fireside chat will be webcast live from the Events section of the company’s website at www.nanobiotix.com. A replay of the webcast will be archived and available for one month following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate– NBTXR3 —which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®. For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Nanobiotix Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com Investor Relations Department Kate McNeil SVP, Investor Relations +1 (609) 678-7388 investors@nanobiotix.com Media Relations France – Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com US – Porter Novelli Dan Childs +1 (781) 888-5106 Dan.childs@porternovelli.com

Nanobiotix (EU:NANO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Nanobiotix Charts.
Nanobiotix (EU:NANO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Nanobiotix Charts.